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Abstract
Background: Pathogenic variants of the lysine acetyltransferase 6A or KAT6A gene are associated with a newly
identified neurodevelopmental disorder characterized mainly by intellectual disability of variable severity and
speech delay, hypotonia, and heart and eye malformations. Although loss of function (LoF) mutations were initially
reported as causing this disorder, missense mutations, to date always involving serine residues, have recently been
associated with a form of the disorder without cardiac involvement.
Results: In this study we present five new patients, four with truncating mutations and one with a missense
change and the only one not presenting with cardiac anomalies. The missense change [p.(Gly359Ser)], also
predicted to affect splicing by in silico tools, was functionally tested in the patient’s lymphocyte RNA revealing a
splicing effect for this allele that would lead to a frameshift and premature truncation.
Conclusions: An extensive revision of the clinical features of these five patients revealed high concordance with
the 80 cases previously reported, including developmental delay with speech delay, feeding difficulties, hypotonia, a
high bulbous nose, and recurrent infections. Other features present in some of these five patients, such as
cryptorchidism in males, syndactyly, and trigonocephaly, expand the clinical spectrum of this syndrome.
Keywords: KAT6A, Neurodevelopmental disease, Clinical genetics, Whole exome sequencing, Clinical
characterization
Background
The lysine acetyltransferase 6A or KAT6A gene (a.k.a.
MYST3 and MOZ; MIM *601408) codes for a member
of the histone acetyltransferase (HAT) family MYST.
This gene was identified at a recurrent break-point of
chromosomal translocations associated with acute
myeloid leukaemia (AML) [1]. KAT6A acetylates lysine-
9 residues in histone H3 (H3K9), playing an essential
role in the regulation of transcriptional activity and gene
expression. KAT6A is also involved in the acetylation
and regulation of the tumor suppressor p53, a key factor
in essential cell processes such as cell arrest and apop-
tosis [2]. Moreover, KAT6A is able to directly bind and
regulate the transcription factors Runx1 and Runx2
through its C-terminal SM (serine and methionine rich)
domain [3].
De novo mutations in KAT6A have recently been asso-
ciated with a syndrome mainly characterized by intellec-
tual disability (autosomal dominant mental retardation
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32; MIM # 616268). To date, a total of 79 patients have
been reported [4–15]. All of them present with develop-
mental delay (DD) or intellectual disability (ID) with
speech delay. Additionally, low muscle tone, problems
with early feeding, and heart and eye defects are fre-
quent [13]. Most of the reported mutations are loss of
function (LoF) variants including splicing mutations,
stop gain, and frameshift changes. Recently, missense
mutations affecting highly conserved residues in relevant
functional sites have also been described [12, 13].
The protein KAT6A is part of the MOZ/MORF com-
plex together with ING5, KAT6B, MEAF6, and one of
BRPF1–3. Neurodevelopmental syndromes have been as-
sociated not only with KAT6A but also with KAT6B and
BRPF1. KAT6B mutations are associated with Say-
Barber-Biesecker-Young-Simpson syndrome (SBBYSS,
MIM # 603736) and Genitopatellar syndrome (MIM #
606170), while BRPF1 mutations associate with IDDDFP
(Intellectual developmental disorder with dysmorphic fa-
cies and ptosis, MIM # 617333). Like KAT6A syndrome,
these two conditions present mainly with DD or ID and
speech delay, hypotonia, and midline facial dysmorphic
features including a broad nose.
Here, we present five new unrelated cases bearing four
truncating mutations and one missense mutation in
KAT6A, and we review the existing literature to expand
the clinical delineation of KAT6A syndrome.
Results
Clinical description
The detailed phenotypic description of the patients is
summarized in Table 1.
Patient 1 (P1)
The patient is a 10-year-old boy from a non-
consanguineous and healthy couple. Two younger sib-
lings, a girl aged 5½ years and a boy aged 3, are healthy.
During the pregnancy of the proband, intrauterine
growth retardation was detected. He was born at 37
weeks by caesarean section with Apgar scores 9/10 at 1
and 5min, respectively. At birth, weight was 2.04 kg
(2nd percentile, − 2.04 SD), height 43 cm (<3rd percent-
ile, − 2.91 SD), and cranial circumference 30 cm (<3rd
percentile, − 3.77 SD). The infant presented dysmorphic
features such a triangular facies, low-set ears, and short
neck, in addition to cryptorchidism. Abdominal and cra-
nial ultrasound studies were performed with no evidence
of malformations. Serology for common neonatal infec-
tions (toxoplasma, rubella, cytomegalovirus, and herpes
simplex) as well as brain computerized tomography
(CT) and funduscopy were normal.
At the 5th month of life, a prominent metopic suture
was observed. The helical CT confirmed craniosynosto-
sis of the metopic suture and ossification of the anterior
fontanelle. At this follow-up visit developmental delay
and limb hypertonia were detected. The subject began to
crawl at 4 years of age and made his first unassisted
steps at age 5. At 9 years of age absence seizures were
clinically suspected and he was treated with valproate,
showing good response. At 11 years the treatment was
discontinued as the patient did not present seizures any-
more and EEG was normal. Brain MRI (magnetic reson-
ance imaging) was always normal. He was also treated
with botulinum toxin because of hypersalivation due to
dysphagia. The boy was also followed-up for severe my-
opia and constipation. He had a non-symptomatic large
atrial septal defect, ASD (ostium secundum type).
At 10 years of age the dysmorphic traits continued,
suggestive of Opitz C syndrome. The patient presented
bulging eyes with true proptosis, mild epicanthus, hypo-
plastic nose, small mouth with normal philtrum and pal-
ate, and normal auricles (see detailed description in
Table 1 and Fig. 1: a, g and l). From the neurological
point of view he presented with spastic tetraparesis, with
ulnar deviation of the hands, wide-base gait (increased
distance between the tibial malleolus when walking) not
in the range of a cerebellar ataxia but denoting clumsi-
ness and a subtle gait disturbance, and flexion of hips
and knees. The patient lacks expressive language, but
has improved his ability to understand and to establish
communication. He does not respond to simple com-
mands and has poor attention span. He is unable to
chew and is fed mashed food. He walks with increased
lift base and can take some steps alone. Usually, he
needs walker support to get around and has no sphincter
control. The patient is currently on physiotherapy and
speech therapy, and pharmacological treatment with ris-
peridone and methylphenidate due to behavioural dis-
turbances and ADHD (attention deficit-hyperactivity
disorder) traits, respectively.
Patient 2 (P2)
The patient is an 11-year-old boy, the first child of
healthy non-consanguineous parents. He was born at
38 + 5 weeks via caesarean section due to breech presen-
tation after an uneventful pregnancy. At birth, weight
was 2.97 kg (30th percentile, − 0.45 SD), length was 49
cm (25th percentile, − 0.28 SD), and cranial circumfer-
ence was 33 cm (10th percentile, − 0.61 SD). On neo-
natal examination, sacral and suprasternal dimples were
observed on ultrasound with normal subjacent tissues
and reducible bilateral inguinal hernia.
The neonatal period was significant for poor feeding,
mild hypertonia of limbs, and delayed gross motor devel-
opment. He achieved head control at 3 months, sitting at
15 months, and crawling and kneeling later than 24
months; currently he walks only with a walker. His
speech was also delayed as he started babbling at 22
Urreizti et al. Orphanet Journal of Rare Diseases           (2020) 15:44 Page 2 of 14
Table 1 Deep dysmorphological phenotyping after clinical evaluation of the 5 patients presented here
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Total
Variant’s genomic position 8:41792353 8:41792098 8:41792310 8:41834814 8:41791480
cDNA change c.3385C > T c.3640A > T c.3427_3428insTA c.1075G > A c.4254_4257
delTGAG




Exon 17/17 17/17 17/17 7/17 17/17
Inheritance De novo De novo De novo De novo De novo 5 de
novo
dbSNP rs786200960 – – – –
GnomAD – – – 1/250564 –
ClinVar – – – – Pathogenic
Current age (years) 16 11 9 8 6 10 av
Gender Male Male Female Male Female 2F/3M
Ethnicity (country of origin) Caucasian (Spain) Caucasian (Spain) Caucasian (Spain) Caucasian (Spain) Chinese
(China)
Neurological
Global developmental delay (HP:0001263)/
Intellectual disability (HP:0001249)
+ (severe) + + + + 5/5
Autistic behaviour (HP:0007229) NE + – + + 3/4
Speech delay (HP:0000750) + + + + + 5/5
Seizures (HP:0001250) + + – + – 3/5
Sleep disturbance (HP:0002360) – + – + – 2/5
Hypotonia (HP:0001290) – – – + + 2/5
Stereotypy (HP:0000733) + + + – + 4/5
Lower limb hypertonia (HP:0006895) + + + – – 3/5
Unstable gait (HP:0002141) + + + + + 5/5
Craniofacial
Microcephaly (HP:0000252) + + + + + 5/5
Triangular face (HP:0000325) + + + – + 4/5
Long face (HP:0000276) + – + + + 4/5
Facial asymmetry (HP:0000324) + – – + (mild) – 2/5
Frontal bossing (HP:0002007) + – – + (central) – 2/5
Midface retrusion (HP:0011800) – + + – + 3/5
Sparse medial eyebrows (HP:0025325) + + + + + 5/5
Arched eyebrows (HP:0002553) + + + + + 5/5
Thin eyebrows (HP:0045074) + + + – – 3/5
Swollen skin on the upper eyelids (HP:
0012724)
– – – + – 1/5
Epicanthal folds (HP:0000286) + (mild) – – + + 3/5
Proptosis (HP:0000520) + – + (mild) – – 2/5
Deep set eyes (HP:0000490) – – + + – 2/5
High nasal bridge (HP:0000426) + – – – + 2/5
Broad nasal tip (HP:0000455) + + + – + 4/5
Bifid nasal tip (HP:0000456) + + + – – 3/5
Prominent columella (HP:0009765) + – – – – 1/5
Low-set ears (HP:0000369) + + + – + 4/5
Anteverted ears (HP:0040080) – – – + + 2/5
Prominent antihelix (HP:0000395) + + + + + 5/5
Prominent antitragus (HP:0008593) – – + + (mild) + 3/5
Hypoplastic tragus (HP:0011272) – + – + – 2/5
Urreizti et al. Orphanet Journal of Rare Diseases           (2020) 15:44 Page 3 of 14
Table 1 Deep dysmorphological phenotyping after clinical evaluation of the 5 patients presented here (Continued)
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Total
Small earlobe (HP:0000385) + – + (mild) + (mild) – 3/5
Short philtrum (HP:0000322) – – + + (mild) – 2/5
Small mouth (HP:0000160) + – – – + 2/5
Wide mouth (HP:0000154) – – + + – 2/5
Prognathism (HP:0000303) – + + – – 2/5
Pointed chin (HP:0000307) + + (mild) + – – 3/5
Ocular
Convergent strabismus (HP:0000565) + (left eye) + + (left eye) – + 4/5
Astigmatism (HP:0000483) – + + – – 2/5
Myopia (HP:0000545) + + – – – 2/5
Amblyopia (HP:0000646) + – + – – 2/5
Nasolacrimal stenosis (HP:0000579) + – + – – 2/5
Conjunctivitis (HP:0000509) – – + – – 1/5
Thorax & Abdomen
Long thorax (HP:0100818) + + + + + 5/5
Narrow thorax (HP:0000774) + + + + + 5/5
Asymmetric chest (HP:0001555) pectus excavatum – – – – 0/5
Wide intermamillary distance (HP:0006610) + + + (mild) + (mild) + 5/5
Low-set nipples (HP:0002562) – + NE + (mild) + 3/4
Inverted nipple (HP:0003186) + (left) – NE – – 1/4
Bulging abdomen (HP:0001538) – – + – + 2/5
Prominent umbilicus (HP:0001544) – – + – – 1/5
Limbs
Skin syndactyly between 3rd and 4th fingers
(HP:0011939)
+ (mild) – – – – 1/5
Upper limb amyotrophy (HP:0009129) + + + + – 4/5
Lower limb amyotrophy (HP:0007210) + + + + – 4/5
Lower limb asymmetry (HP:0100559) – – + NE – 1/4
Genu valgum (HP:0002857) + – + (mild) – – 2/5
Genu varum (HP:0002970) – – – + (mild) – 1/5
Enlargement of the proximal interphalangeal
joints (HP:0006185)
+ + (mild) – – – 2/5
Pes planus (HP:0001763) + + + + – 4/5
Deviation of the hallux (HP:0010051) + – + – – 2/5
Short halluces (HP:0010109) – – + (mild) + – 2/5
Sandal gap (HP:0001852) – – – + – 1/5
Hammertoe (HP:0001765) – – – + – 1/5
Other
Prenatal problems (HP:0001197) IUGR – Mild pyelectasis in
left kidney; IUGR
– – 2/5







Respiratory problems (HP:0002795) – + – – – 1/5
Genitourinary problems (HP:0000119) Small testis and penis; No
sphincter control
– – Abnomal sphincter
control
– 2/5
Feeding problems (HP:0011968) + + + + + 5/5
Freckling (HP:0001480) Freckles on the thorax Numerous freckles
(face and body)
– – – 2/5
Webbed neck (HP:0000465) – – – – – 0/5
Av average, IUGR Intrauterine growth retardation. NE Not Evaluable
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Fig. 1 Images depicting key phenotypic features of the cases presented here. a Patient 1 facies at 16 years of age, b and c Patient 2 facies at 11
years, d Patient 3 facies at 9 years, e Patient 4 facies at 8 years, and f Patient 5 facies at 6 years. Panels g to k show the patient’s gestalt (at the
same age as the facies figure). l Patient 1 hand. m and n Patient 5 ft and hands
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months. His fine motor skills have improved with ther-
apy; he is able to grab objects and play with both hands.
Recurrent pneumonias were diagnosed with several hos-
pital admissions, and dysphagia to liquids was observed,
requiring thickeners. At age 2 years, an echocardiogram
showed a 12-mm small ASD, ostium secundum type that
was occluded with vascular plug system. Testing for in-
born errors of metabolism (with plasma amino acids,
acylcarnitine profile, total and free carnitines, and urine
organic acids) was negative.
At age 6 years, he presented 2 episodes of loss of con-
sciousness but electroencephalogram (EEG) did not con-
firm electric seizures. He was treated with valproic acid,
currently on withdrawal. Brain MRI showed areas of
polymicrogyria on the posterior right insula, delayed
myelination, and slight descent of the cerebellar tonsils
through the foramen magnum (Arnold-Chiari
malformation).
On physical examination at age 11 years (Table 1 and
Fig. 1: b, c and h), the patient was found to have a short
stature (height 113 cm, <3rd percentile, − 4.75 SD),
microcephaly (cranial circumference of 49.5 cm, <3rd
percentile, − 3.74 SD), and dysmorphic facial features
such as flat facies, hypertelorism, mildly blue sclera and
proptosis, full lower lip and protruding tongue that led
to an open mouth expression, and low-set dysplastic
ears. Ocular abnormalities included endotropia, astigma-
tism, and myopia. Additionally, the patient had one right
supernumerary nipple, a single palmar crease on the
right hand, poor palmar sulcation, and mild fifth finger
clinodactyly in both hands. Neurologically, he showed
intellectual disability, poor eye contact, generalized
hypertonia, the need for a stroller to walk, and absence
of comprehensible language, but with babbling. He pre-
sents midline manual stereotypies and suffers sleep dis-
turbances with frequent awakenings.
Patient 3 (P3)
The patient is a 9-year-old female, the only child of
healthy non-consanguineous parents. Intrauterine
growth retardation and mild left pyelectasis were de-
tected during pregnancy. Birth weight was 2.30 kg (1st
percentile, − 2.25 SD) and cranial circumference was
30.5 cm (<3rd percentile, − 3 SD). Screening for congeni-
tal disorders of metabolism was negative. Feeding diffi-
culties and oral candidiasis were observed during the
perinatal period. The subject achieved head control at 2
months, sat up at 10–12months, began to crawl at 23
months, and presented unstable gait at age 3. At age 2,
she was diagnosed with beta-thalassaemia minor (of pa-
ternal inheritance). Mild valvular pulmonary stenosis
was also observed, although this problem had disap-
peared by 6 years of age. EEG was normal at the age of
3 years. Brain MRI, performed at few months of age,
showed unspecific delayed myelination, although re-
peated imaging was considered normal when the patient
was 3 years old.
At 6 years of age, when she was recruited by the Spai-
nUDP (Spanish Undiagnosed Rare Diseases Program,
http://spainudp.isciii.es/), she had global developmental
delay, intellectual disability, language impairment, ste-
reotypies, astigmatism, amblyopia, and recurrent con-
junctivitis. Her physical exam showed craniofacial
dysmorphisms including microcephaly, midface retrac-
tion, mild hypoplasia of the ear lobe, prominent antitra-
gus, sparse medial eyebrows, proptosis, strabismus,
broad and bifid nasal tip, short philtrum, prognathism,
and big mouth (Table 1 and Fig. 1: d and i). She also
had wide intermammillary distance, bulging abdomen,
protruding umbilicus placed on a small depression of
the abdomen, mild genu valgo, pes planus, and fibular
deviation of halluces.
Patient 4 (P4)
The patient is an 8-year-old boy, the only child of non-
consanguineous parents. No problems were detected
during pregnancy and the neonatal period. He was born
at term with a birth weight of 3.7 kg (76th percentile, +
0.70 SD) and a cranial circumference of 35 cm (34th per-
centile, − 0.42 SD). He achieved head control at 3
months, sat up at 8.5 months, and began to walk inde-
pendently at 16 months. Microcephaly was detected at 2
months of age and he was diagnosed with atypical ab-
sences with eyelid myoclonias at the age of 16 months.
He was treated with valproate from 21months to 5 years
with acceptable control of seizures. When the proband
was 5 years old, it was withdrawn due to its association
with adverse reactions (nauseas, vomiting, and weight
loss). A few months later, valproate treatment was ad-
ministered again since the number and intensity of epi-
leptic crises had increased. In this recurrence of epilepsy,
ethosuximide was needed together with valproate to
achieve seizure control. Several EEGs carried out starting
at age 3 years have disclosed spike-wave anomalies.
When he was admitted to SpainUDP, at 6 years of age,
the subject showed intellectual disability with altered
fine motor coordination, unstable gait with frequent
falls, language impairment, and autistic behaviour. He
has always had sleep disturbances and hyporexia. Hypo-
tonia with reduced muscle bulk has also been observed.
Physical examination (Table 1 and Fig. 1: e and j)
showed microcephaly, long face, mid facial asymmetry,
frontal central bossing, swollen skin on the upper eye-
lids, epicanthus, deep set eyes, mildly everted lower eye-
lid in its external part, and deep horizontal groove under
the lower lip. Additional features include a slender ap-
pearance, scarce body adiposity, long and narrow thorax,
mild genu varo (bilateral), pes planus, short halluces,
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sandal gap between the first and second toes, and flexed
fifth toes.
Metabolic testing (including urine organic acids and
glucose in cerebrospinal fluid) was normal. Brain MRI
was normal.
Patient 5 (P5)
The patient is a 6.5-year-old girl, first child of healthy
non-consanguineous parents and with a healthy younger
sister. The subject was born at term with an uneventful
delivery and with a birth weight of 3.14 kg (42nd per-
centile, − 0.2 SD), a cranial circumference of 33 cm (10th
percentile, − 0.61 SD), and Apgar 9/10 at 1 and 5min.
New-born screening for inborn errors of metabolism
was normal. She had feeding problems from the neo-
natal period. During her hospital admission for dyspha-
gia at 2 months of age, an atrial septal defect (ASD) was
detected, which was surgically repaired at 16 months.
She had delayed motor skills, with head control at 6
months, sitting up at 13 months, crawling at 16 months,
and autonomous although unstable gait developing at
age 2.
The subject has received physical, speech, and behav-
ioral therapies and has attended a special school since 6
years of age. She is not able to talk, shows difficulties in
adapting to new environments, shows significant behav-
ioral problems with particular impact on the social do-
main, and has poor eye contact. Physical examination
(Table 1 and Fig. 1: f, k, m and n) showed dysmorphic
features characterized by midface hypoplasia, almond-
shaped eyes, and slightly upslanted palpebral fissures,
and absent Cupid’s bow. Ears have underdeveloped anti-
helix, and are slightly low set, with increased posterior
angulation. The hands show a complex palmar dermato-
glyphic pattern with abnormal square radial border
morphology. Tone, strength, and deep tendon reflexes
are normal.
Remarkably, cranial MRI at age 6 revealed prominent
cerebellar interfolia space compared with a previous
MRI at 2 years of age; this is compatible with progressive
cerebellar atrophy. No other significant alterations were
detected on MRI. The subjected was recruited by the




A normal karyotype (46, XY) was determined. A trio-
based whole exome study (WES) revealed a de novo het-
erozygous variant NM_006766:c.3385C > T (p.Arg1129*)
in the KAT6A gene, which was confirmed by Sanger se-
quencing. This change was previously identified in a
child with global developmental delay [5].
Other variants of unknown clinical relevance (VUS)
are summarized in Additional file 1: Table S1.
Patient 2
Karyotype, subtelomeric fluorescent in situ hybridization
(FISH), kit MLPA panel studying recurrent genomic dis-
orders (SALSA® P245-B1), chromosomal microarray, and
testing for fragile X, MECP2/FOXG1 genes, Angelman
syndrome, Pitt-Hopkins syndrome, mucopolysacchari-
doses, and congenital disorders of glycosylation, yielded
normal results. Clinical exome of the index case revealed
a heterozygous de novo variant in KAT6A in the pro-
band (NM_006766: c.3640 A > T (p.Lys1214*)]. Other
VUS detected in the patient were: heterozygous
c.852G > A (p.Leu284Leu) variant and heterozygous
c.1467 + 16A > C variant in the FOXG1 gene (Sup.
Table 2).
Patient 3
Prior genetic and metabolic testing included karyotype,
FISH at 4p16.3, array-CGH, and 7-dehydrocholesterol
testing, all negative. Trio-based WES revealed a hetero-
zygous de novo variant (NM_006766:c.3427_3428insTA)
in KAT6A in the proband, which was confirmed through
Sanger sequencing. This frameshift variant consists of an
insertion of two nucleotides at exon 17 and it leads to
the premature termination of the protein (p.Ser1143-
Leufs*5). The variant has not been previously described
in the genomic databases.
Patient 4
Before WES, several genetic tests were carried out, with
negative results: karyotype, array-CGH (60 K), Fragile X,
Angelman, and diagnostic exome sequencing (DES) for
epilepsy (543 genes). Trio-based WES was performed
and a de novo KAT6A variant was identified in the pa-
tient (NM_006766:c.1075G > A), which was confirmed
through Sanger sequencing. This variant predicts a re-
placement of guanine by adenine at codon 359 in exon 7
[p.(Gly359Ser)]. It has been found in only one carrier
out of 250,564 alleles in gnomAD. It is predicted to be
‘deleterious’ or ‘putatively pathogenic’ by a variety of bio-
informatic tools (PolyPhen2, Mutation Taster) and to be
‘tolerated’ by SIFT (score 0.28); CADD score is 16.9.
Altogether, this variant is classified as ‘pathogenic’ ac-
cording to the AMCG/AMP 2015 guidelines. In
addition, the Human Splicing Finder software (3.1 ver-
sion; January 10, 2018) predicts a potential alteration of
splicing consisting of the generation of a cryptic ac-
ceptor site (AGTTCGAACTAGCC) at exon 7 (which
was not experimentally observed, see below), and the
loss of a predicted ESE (GGCCCTGG) for splicing factor
SC35 (starting at c.1075G, which is not present in the
mutant allele).
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Table 2 Clinical overview of KAT6A syndromic patients





et al. 2019 [14]
Kennedy et al. 2019
[13]
Total
Features LTa Mb M LT LT ET LT M ET LT M Overall %
Protein change 2FS;
2NS











Gender (F/M) 2/2 0/1 1/1 0/1 0/1 8/10 25/23 2/4 8/10 27/27 3/6 38/43
Perinatal features
Small for gestational age 2/4 0/1 2/2 NR 0/1 2/15 8/44 0/4 2/15 10/49 2/7 14/71 20
Feeding difficulties/failure
to thrive








4/4 1/1 2/2 1/1 1/1 18/18 44/44 4/4 18/18 50/50 7/7 75/75 100
Speech delay/Absent
speech
4/4 1/1 1/2 1/1 1/1 18/18 44/44 5/5 18/18 50/50 7/8 75/76 99
Unstable/abnormal gait 4/4 1/1 0/2 1/1 1/1 1/3 NR 0/0 7/9 1/3 8/12 67
Neonatal hypotonia 2/4 1/1 1/1 1/1 NR 8/18 40/47 5/6 8/18 43/52 7/8 58/78 74
Seizures 2/4 1/1 1/2 1/1 0/1 2/17 2/47 1/6 2/17 5/53 3/9 10/79 13
Sleep disturbance 1/4 1/1 NR NR NR 3/16 15/28 2/4 3/16 16/32 3/5 22/53 42
Autistic behavior/behavioral
problems
2/3 1/1 NR NR NR 4/15 8/18 3/3 4/15 10/21 4/4 18/40 45
Craniofacial features
Microcephaly 4/4 1/1 2/2 1/1 0/1 1/18 20/45 1/15 1/18 25/51 1/5 27/74 36
Frontal bossing/large
forehead
1/4 1/1 NR 1/1 0/1 0/1 1/4 NR 0/1 3/10 1/1 4/12 33
Bitemporal narrowing 1/4 0/1 0/2 1/1 0/1 NR 3/3 NR NR 5/9 0/3 5/12 42
Ear anomalies
(large, low set, rotated,
small earlobe …)
4/4 1/1 NR 1/1 NR NR 9/11 0/1 NR 14/16 1/2 15/18 83
Palpebral ptosis 1/4 0/1 1/2 0/1 NR 3/18 7/45 0/6 3/18 8/50 1/9 12/77 16
Eye anomalies (proptosis,
hypertelorism, deep set,)
4/4 1/1 2/2 1/1 1/1 NR 3/8 1/1 0/0 9/14 4/4 13/18 72
Epicanthal folds 2/4 1/1 0/2 NR 0/1 NR 2/7 0/1 0/0 4/12 1/4 5/16 31
Broad/bulbose nasal tip 4/4 0/1 2/2 1/1 0/1 16/18 35/40 3/5 16/18 40/46 5/8 61/72 85
Thin upper lip 0/4 0/1 2/2 0/1 1/1 7/17 28/38 2/4 7/17 29/44 4/7 40/68 59
Micrognathia 0/4 0/1 0/2 0/1 0/1 NR 6/12 0/1 0/0 6/18 0/4 6/22 27
Ocular problems
Strabismus 4/4 0/1 2/2 NR NR 9/17 27/47 1/5 9/17 31/51 3/8 43/76 57
Visual defects 4/4 0/1 2/2 NR NR 9/17 26/38 1/3 9/17 30/42 3/6 42/65 65
Other features
Congenital heart defect 4/4 0/1 0/2 NR 0/1 5/18 32/46 0/6 5/18 36/51 0/9 41/78 53
Reflux 2/4 0/1 NR NR NR 7/18 27/38 3/6 7/18 29/42 3/7 39/67 58
Constipation 1/4 0/1 1/2 NR NR 4/16 18/28 3/6 4/16 19/32 4/9 27/57 47
Recurrent infections 1/4 0/1 NR NR NR 5/16 24/34 1/5 5/16 25/38 1/6 31/60 52
AF Anterior fontanelle, CVI Cortical visual impairment, Del Deletion, ET Early truncating, FS Frameshift, GERD Gastroesophageal reflux disease, LT Late
truncating, M Missense, NR not reported, NS nonsense, PDA Patent ductus arteriosus; Features present in more than 60% of the patients are indicated
in bold with % of the total
a Patients 1–3 and 5. b Patient 4
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Patient 5
The subject has a normal karyotype (46,XX) and mo-
lecular karyotype by array-CGH (60 K). Singleton WES
was performed followed by trio-based segregation with
Sanger sequencing. The analysis showed a heterozygous
de novo frameshift deletion of four nucleotides (NM_
006766: c.4254_4257delTGAG) in exon 17 of the
KAT6A gene, already defined as ‘pathogenic’ in ClinVar
and reported by Kennedy et al. [13]. The mutant mRNA
is predicted to be translated as a truncated protein with
a premature termination 12 amino acids after the frame-
shift (p. Glu1419Trpfs*12). The variant has not been de-
scribed in healthy population in the genomic databases.
KAT6A expression analysis
Since pathogenic KAT6A mutations are usually truncat-
ing, and given that predictors indicate that the
c.1075G > A variant identified in patient 4 may be affect-
ing splicing mechanisms, we analysed the KAT6A spli-
cing pattern of this patient using mRNA from peripheral
blood cells. Expression analysis showed two bands: a
normal amplicon of 552 bp and a shorter amplicon of
167 bp (with very low intensity) corresponding to an ab-
errant splicing (Fig. 2a). Sanger sequencing of this minor
fragment revealed the loss of exon 7 (consistent with the
predicted loss of an ESE), and of 65 additional bp of
exon 6 (indicative of the use of a non-canonical cryptic
donor site, Fig. 2b). The putative translation of this aber-
rant mRNA would involve a frameshift leading to a pre-
mature early termination codon (p.Arg330Serfs*13),
potentially leading to nonsense mediated decay (NMD).
The sequencing of the upper band showed both alleles
(wild type and mutant), demonstrating that the allele
carrying the missense mutation is mostly correctly
spliced (Fig. 2c).
Discussion
Since 2015, around 80 cases of syndromic intellectual
disability due to mutations at the KAT6A gene have
been described in the literature, delineating a new syn-
drome with variable presentation (Table 2 and Fig. 3)
[4–15]. Here, we present 5 patients with de novo vari-
ants at KAT6A, four ‘late truncating’ and one missense
variant, and we describe their clinical presentations, add-
ing further clinical and molecular delineation to the
KAT6A syndrome. The four late truncating mutations
(in patients P1–3, and 5) are in the last exons and are
thus predicted to escape NMD. The phenotypes of these
patients are similar to those with late truncating muta-
tions described by Kennedy et al. [13].
The main characteristic feature of this syndrome is
neurological involvement. All five patients presented
with moderate or severe developmental delay or intellec-
tual disability with severe involvement of speech and
expressive language being more affected than compre-
hension, as in nearly all KAT6A syndrome patients [13].
Also, all patients described here presented with motor
delay, and two of them showed similar manual stereoty-
pies (hand flapping or fluttering), a feature that has not
been highlighted in previous reports. This finding com-
bined with the poor eye contact and language impair-
ment could represent part of the autistic spectrum
behaviour, one of the most frequent and significant
neurological symptoms. In addition, 3 out of the 5 pa-
tients presented here suffered epilepsy, a manifestation
reported in only 13% of the previously described series.
While craniofacial dysmorphic features are present in
all the patients, some of them are very unspecific and
some patients present very mild alterations [12, 14],
which renders clinical identification of this syndrome
very challenging. Nevertheless, some facial similarities
can be identified in several patients (such as P2 and P3).
All five patients presented with microcephaly. Micro-
cephaly has been reported in 36% of all patients, and
nearly in half of the patients with late truncating muta-
tions, but it is less frequent in patients bearing missense
or early truncating mutations (Table 2). Also, patient 1
presented with trigonocephaly due to synostosis of the
metopic suture. Different kinds of craniosynostoses have
been previously reported [4], including sagittal synos-
tosis [8, 13] and scaphocephaly [10]. Frontal bossing
and/or bitemporal narrowing is reported in 30–40% of
patients. In general, a broad/bulbous nasal tip is present
in the majority of patients (86%) together with ocular
anomalies (such as hypertelorism, proptosis or deep set
eyes and downslanting palpebral fissures [6, 9, 12]),
mouth anomalies (down-turned corners of the mouth
[9] or protruding tongue [6, 7]) and ear anomalies (large,
low set, rotated …), present in all five patients reported
here. Joint hypermobility, a frequent finding in these five
patients, has also been previously reported [9]. Other
clinical findings previously reported are supernumerary
nipple [6], cryptorchidism [6], and syndactyly [6].
Interestingly, all the present patients except for patient
4 (bearing a missense mutation) presented with congeni-
tal heart defects. Cardiac defects have been reported in
around 70% of patients bearing late truncating muta-
tions, but not hitherto in patients with missense muta-
tions. Brain abnormalities, found in three of our patients
(Patients 2, 3 and 5), have been frequently reported, in-
cluding delayed myelination [13] and benign enlarge-
ment of the pericerebral areas [9], with the lack of the
olfactory bulb [6] and pituitary abnormalities [11] being
the two most consistent and noteworthy midline neuro-
imaging findings.
All five patients presented with feeding difficulties or
failure to thrive, and patients 2, 4, and 5 also presented
with neonatal hypotonia, traits reported in more than
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Fig. 2 mRNA analysis of mutation c.1075G > A identified in Patient 4. a RT-PCR of KAT6A fragment including exon 5 to 8 in the patient (P), his
mother (M) and father (F), and a control sample (C+). b Schematic representation of the normal (upper) and aberrant (lower) splicing of KAT6A
exons 5 to 8 and chromatogram of exon 6–8 joining point in the smaller band of the patient. c Chromatograms of the mRNA amplification
products in the mother and the patient upper band
Fig. 3 Schematic representation of KAT6A and localization of pathogenic variants, at the protein level (upper panel) and the exonic gene
structure (scaled). (1) p.Cys1096Phefs*27; p.Cys1096Leufs*6; p.Cys1096Serfs*6; (2) p.Leu1219Thrfs*75; p.Leu1219Tyrfs*75; (3) p.Gln1348Argfs*7;
p.Gln1348*; (4) Mediates interaction with BRPF1, required for histone H3 acetyltransferase activity; (+) activation. In bold, missense mutations.
Underlined, mutations identified in the patients presented here
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70% of the KAT6A patients. Severe food allergies have
been previously reported in 3 patients [8] and cow’s milk
intolerance was noted in patient 42 in Kennedy et al.
[13], although it is not clear if this is associated with mu-
tations in KAT6A. None of the patients reported here
presented with food intolerances or allergies.
Recurrent infections, observed in two patients of our
cohort with late truncating variants, have been reported
in nearly half of the previously published patients and in
71% of patients bearing late truncating variants [13].
This observation is in agreement with the improper B
cell differentiation reported in the conditional KO mur-
ine model [16] and with the role of KAT6A as an essen-
tial factor for long-term repopulation of hematopoietic
stem cells [17].
While the majority of KAT6A syndromic mutations
are truncating, missense mutations have recently been
described [12, 13]. Here we present a case with clinical
characteristics similar to the rest of KAT6A patients,
bearing the de novo missense mutation p.Gly359Ser.
While KAT6A is clearly constrained against LoF variants
(with a pLI = 1 and oe = 0.02, gnomAD accessed June
2019), it is not constrained for missense mutations, with
an oe = 0.83, clearly above the recommended CI < 0.35.
All the previous missense mutations associated with
pathogenicity affect highly conserved residues in critical
functional regions of the protein [13]. In addition, it is of
note that all these changes involve serine residues, either
eliminating an existing Ser or introducing a new one, as
in the case of p.Gly359Ser, reported in patient 4. KAT6A
C-terminal domain contains a serine- and methionine-
rich domain that is essential for its binding to the tran-
scription factor Runx2 [3]. As the hydroxyl group of
serine is highly reactive and is able to form hydrogen
bonds with a variety of polar substrates, the alteration of
their number and position seems to be especially critical
in KAT6A, otherwise tolerant of missense substitutions.
In addition, we have verified that this variant can affect
normal processing of pre-mRNA by producing an aber-
rant splicing consisting of the loss of exon 7 and 65 bp
of exon 6. This mutation leads to early truncation and is
assumed to be affected by the NMD process, reducing
total KAT6A mRNA. It should be noted that this alter-
ation seems to have a minor impact. It is likely that the
pathological consequences of this variant are mainly due
to the amino-acid substitution, leading to a deficit of
functional KAT6A. Concordantly, the patient did not
present with cardiac alterations, similar to the majority
of patients bearing missense mutations.
Conclusions
With this study, we have expanded the clinical delinea-
tion of KAT6A syndrome, an emerging and distinctive
entity which is potentially clinically diagnosable. Given
the severity of its clinical features and its reproductive
implications, it is important to make an early diagnosis
of this condition, including identification of those pa-
tients bearing missense mutations.
Material and methods
Biological samples
Genomic DNA of the patients and their parents was ob-
tained from peripheral blood at the respective institu-
tions (Hospital La Fe, Valencia, for P1, Hospital Sant
Joan de Deu, Barcelona, for P2, Instituto de Salud Carlos
III, Madrid, for P3 and P4, and Hospital del Mar, Barce-
lona, for P5). Signed informed consent was obtained
from each patient’s parents. All protocols were approved
by the ethics committee of each of the institutions and
all methods were performed in accordance with the rele-
vant guidelines and regulations.
Whole exome sequencing and molecular analyses
Patient 1
Whole exome sequencing of the proband and his par-
ents was performed in the National Centre of Genomic
Analysis (CNAG; Barcelona, Spain) using the Illumina
HiSeq-2000 platform. Exome capture was performed
with Agilent SureSelect v5 (Agilent, CA, USA). The sam-
ples were sequenced at a coverage of 140x. The data
were analyzed as described elsewhere [18]. Annotation,
filtering, and prioritization of variants were carried out
using VarAFT software [19]. The results were then fil-
tered under de novo dominance and recessive hypoth-
eses. Variants with a minimum allele frequency (MAF)
above 0.001 for AD filtering and above 0.01 for AR fil-
tering in the common population (according to Gno-
mAD) were excluded. Variants in genes included in
DDG2P (The Development Disorder Genotype-
Phenotype Database [15, 20]), and covered by at least 10
reads, were prioritized for validation (it should be noted
that those who carried out the original DECIPHER ana-
lysis and collection of the data bear no responsibility for
the further analysis or interpretation of it).
The mean coverage was of 153.43, 174.29, and 160.829
reads for the patient, father and mother respectively, and
97.2–97.9% of the target region was covered with at least
10 reads (C10). A total of 5 variants in 4 genes were se-
lected for validation by Sanger sequencing. Primer se-
quences and PCR conditions are available on request.
PCR reaction, purification, and sequencing were per-
formed as described previously [20].
Patient 2
Whole exome sequencing of the index case was carried
out with the platform Illumina NextSeq500, using the
Agilent SureSelect v6 QXT capture kit. For the analysis,
several bioinformatics tools were used. The exome
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design covered approximately 95% of the coding regions
of the analysed genes. The sequences used as reference
can be found at the RefSeq database. The estimated fre-
quencies were calculated from the 1000 genomes,
Complete Genomics and NHLBI Exome Sequencing
Project databases. The nomenclature of mutations was
based on the recommendations of the Human Genome
Variation Society. The analysis was carried out according
to the recommendations of the American College of
Medical Genetics. The results were then filtered under
de novo dominance and recessive hypotheses. Variants
with a minimum allele frequency (MAF) above 0.001 for
AD filtering and above 0.01 for AR filtering in the com-
mon population (according to GnomAD) were excluded.
Variants in genes included in DDG2P (The Development
Disorder Genotype-Phenotype Database [21, 22]), and
covered by at least 10 reads, were prioritized for valid-
ation (it should be noted that those who carried out the
original DECIPHER analysis and collection of the data
bear no responsibility for the further analysis or inter-
pretation of it).
Patient 3
After exhaustive revision of clinical information of pa-
tient 3, she was admitted to the Spanish Undiagnosed
Rare Diseases Program (SpainUDP) [23]. Also, this pa-
tient and her unaffected biological parents were enrolled
in the FP7-funded ‘2016 BBMRI-LPC WES Call’ (Euro-
biobank website, accessed on 19th July 2018) to carry
out the research shown in this article.
Trio-based whole exome sequencing (WES) for this
project was conducted at the Centro Nacional de Análi-
sis Genómico (CNAG-CRG, Spain). SureSelect Human
All Exon V5 (Agilent Technologies) was used to perform
whole exome enrichment following the manufacturer’s
instructions. The captured libraries were sequenced
using TruSeq SBS Kit v3-HS (Illumina, Inc), in paired-
end mode with a read length of 2x100bp. On average,
92x median coverage for each sample was generated in a
fraction of a sequencing lane on HiSeq2000 following
the manufacturer’s protocol. Images analysis, base call-
ing, and quality scoring of the run were processed using
the manufacturer’s software Real Time Analysis (RTA
1.13.48, HCS 1.5.15.1) and followed by generation of
FASTQ sequence files by CASAVA. High-quality reads
were aligned to the decoy version of the GRCh37 refer-
ence genome used by the 1000 Genomes Project
(hs37d5) using BWA-MEM (version 0.7.8), and variants
were identified following GATK Best Practices [24]
using HaplotypeCaller (version 3.6). All variants with a
minimum coverage of 8 reads and minimum genotype
quality (GQ) of 20 were uploaded to the Genome-
Phenome Analysis Platform (RD-Connect GPAP) [25,
26] for variant filtration and prioritization. Additionally,
phenotypic terms were extracted from clinical docu-
ments stored in the patient registry by a member of
SpainUDP, mapped to HPO (Human Phenotype Ontol-
ogy) [27] terms, and uploaded to PhenoTips [28], a soft-
ware tool available in the RD-Connect GPAP. This
platform allows filtering and refining of the results by
mode of inheritance, population frequencies, in silico
pathogenicity prediction tools, and HPO codes [25, 26].
This filtering process was carried out by two independ-
ent researchers of SpainUDP with common criteria, and
the results were compared in order to reach a consensus
on selection of the candidate variants, which were con-
firmed by Sanger sequencing in all family members. Fi-
nally, various sources of information were consulted to
build a report with a detailed review of the scientific evi-
dence supporting the correlation between the detected
causative variant and the proband’s phenotype.
Patient 4
Patient 4 was admitted to the SpainUDP and underwent
phenotypic analysis following the standard criteria estab-
lished by this program [23]. After peripheral blood gen-
omic DNA isolation of patient 4 and his biological
parents (see case 3 for details), trio-based WES and se-
lection of candidate variants were performed as de-
scribed by López et al. [23]. Variants assessed as
pathogenic and possibly contributing to the proband’s
phenotype were validated by Sanger sequencing in the
full trio.
Patient 5
Patient 5 was admitted to the URDCat Program after
deep phenotyping. Patient’s whole exome sequencing
from extracted DNA from peripheral blood was carried
out at the National Centre of Genomic Analysis (CNAG;
Barcelona, Spain) using the Illumina HiSeq-2000 plat-
form. Exome capture was performed with Nimblegen
SeqCap EZ MedExome + mtDNA 47Mb and the sam-
ples were sequenced at coverage of 90x. Sequencing data
were analysed according to the project’s established
pipeline, and afterwards SNV, indel, CNV, and mosai-
cism analysis was performed using the RDCat Genomic
Analysis Platform. Variants assessed as pathogenic and
possibly contributing to the proband’s phenotype were
validated by Sanger sequencing in the trio.
Gene expression analysis
In the case of patient 4, gene expression of KAT6A tran-
scripts was evaluated in peripheral blood cells obtained
from the proband and his progenitors. RNA was ex-
tracted from cells using RNeasy Mini Kit (Qiagen), and
then reverse transcribed by Moloney Murine Leukemia
Virus Reverse Transcriptase (M-MLV RT) (Promega),
with 0.5 μg random hexamers (Thermofisher) and 1 μg
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total RNA. Reactions were incubated for 60 min at 37 °C
in a thermocycler. Primer sequences for expression ana-
lysis were designed at exons 5 and 8, as follows:
KAT6A_E5F: 5′-CCGAGGTTTTCACATGGAGT-3′
and KAT6A_E8R: 5′-CGCTCCTCATTTTCTTGT
TTGC-3′. The ACTB gene was used as reference.
Supplementary information
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1186/s13023-020-1317-9.
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